Observational studyAbdominal radiology (New York)2026
Lymph node morphology as an MRI biomarker for microsatellite instability in rectal cancer.
Observational study in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Uncertainty-aware and causal test-time adaptive foundation model for robust colorectal cancer pathology diagnosis.NPJ digital medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMicrosatellite instability (MSI) status in rectal cancer has significant implications for treatment selection, particularly regarding immunotherapy eligibility. This study aimed to evaluate the preoperative magnetic resonance imaging (MRI) features, specifically regional lymph node morphology, in predicting MSI status in rectal cancer patients.
methodsThis retrospective, single-center observational study analyzed 80 patients with histopathologically confirmed rectal cancer who underwent preoperative MRI and MSI/mismatch repair protein expression analysis between August 2021 and January 2025. Two experienced radiologists independently assessed radiological features through consensus reading. Evaluated parameters included tumor localization, T-stage, growth pattern, volume, apparent diffusion coefficient values, T2 signal characteristics, and lymph node features encompassing necrosis presence, contour characteristics, location, and short-axis diameter. Statistical analysis employed univariate and multivariate logistic regression to identify independent predictors of MSI status.
resultsAmong 80 patients, 23 (28.8%) were MSI-positive and 57 (71.2%) were MSI-negative. Multivariate analysis identified three independent predictors of MSI positivity: lymph node necrosis on T1-weighted contrast-enhanced MRI (OR: 7.86, 95% CI: 1.68-36.79, p = 0.010), intermediate-risk tumor T-stage (T3b) (OR: 6.19, 95% CI: 1.43-26.68, p = 0.015), and polypoid growth pattern (OR: 6.14, 95% CI: 1.06-35.54, p = 0.043). Lymph node necrosis demonstrated significantly higher prevalence in MSI-positive patients compared to MSI-negative patients (26.1% vs. 7.0%, p = 0.029).
conclusionsLymph node necrosis on T1-weighted contrast-enhanced MRI, intermediate-risk T-stage (T3b), and polypoid growth pattern serve as valuable radiological biomarkers for predicting MSI status in rectal cancer. These imaging features enable preoperative patient stratification, facilitating personalized treatment planning and appropriate selection of candidates for immunotherapy.
Indexed as
Identifiers
40813620What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.